Skip to main content

Table 3 Frequency of intrathecal IgM and IgA synthesis, IgM and IgA CSF/serum ratios, intrathecal IgM and IgA fractions, amount of locally produced IgM and IgA, and absolute IgM and IgA concentrations in the CSF and serum

From: Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients

  Units Total Attack Remission Acute MY subgroup Acute ON subgroup Acute BRAIN subgroup
Intrathecal IgM synthesis
 QIgM > Qlim(IgM) Samples 13/112 (12%) 13/84 (15%) 0/20 (0%) 9/38 (24%) 3/39 (8%) 1/6 (17%)
 QIgM, all LPs - 0.5 (0-13.8; 111) 0.6 (0-13.8; 83) 0.5 (0-4.1; 20) 1.11 (0-13.81; 38) 0.41 (0-1.82; 38) 0.28 (0-1.9; 6)
 QIgM, if positive - 1.9 (0.6-9.6; 13) 1.9 (0.6-9.6; 13) n.a. 2.72 (0.63-9.63; 9) 0.84 (0.68-1.33; 3) 1.9 (1.9-1.9; 1)
 IgM IF, all LPs % IgM (CSF) 0 (0-59.1; 111) 0 (0-59.1; 83) 0 (0-0; 20) 0 (0-59.1; 38) 0 (0-41.9; 38) 0 (0-18.3; 6)
 IgM IF, QIgM positives % IgM (CSF) 9.2 (1-59.1; 13) 9.2 (1-59.1; 13) n.a. (n.a.;0) 9.2 (3.5-59.1; 9) 9 (1-41.9; 3) 18.3 (18.3-18.3; 1)
 IgM IF, > 10% Samples 6/111 (5.4%) 6/83 (7.2%) 0/20 (0%) 4/38 (10.5%) 1/38 (2.6%) 1/6 (16.7%)
 IgM Loc, all LPs mg/l 0 (0-2.3; 108) 0 (0-2.3; 81) 0 (0-0; 19) 0 (0-2.3; 36) 0 (0-0.3; 38) 0 (0-0.6;6)
 IgM Loc, QIgM positives mg/l 0.32 (0.01-2.3; 13) 0.32 (0.01-2.3; 13) n.a. 0.3 (0.1-2.3; 9) 0 (0-0.3; 3) 0.6 (0.6-0.6; 1)
 IgM CSF mg/l 0.5 (0-16.3; 110) 0.5 (0-16.3; 82) 0.49 (0-3.6; 19) 1.69 (0-16.3; 36) 0.36 (0-1.51; 39) 0.25 (0-4.19; 6)
 IgM serum g/l 1.02 (0.15-3.73; 112) 1.03 (0.15-3.73; 84) 0.89 (0.39-2.19; 20) 1.18 (0.3-2.96; 37) 0.94 (0.15-2.41; 40) 1 (0.79-3.73; 6)
Intrathecal IgA synthesis
 QIgA > Qlim(IgA) Samples 5/111 (5%) 4/83 (5%) 1/20 (5%) 2/38 (5.3%) 2/38 (5.3%) 0/6 (0%)
 QIgA, all LPs - 2 (0-17.3; 110) 1.9 (0-17.3; 82) 2.5 (0-11.1; 20) 2.65 (0-17.27; 38) 1.51 (0-3.22; 37) 2.15 (0-3.26; 6)
 QIgA, if positive - 2.6 (1.7-6.2; 5) 2.4 (1.7-6.2; 4) 2.9 (2.9-2.9; 1) 4.42 (2.61-6.24; 2) 1.96 (1.68_2.24; 2) n.a. (n.a.; 0)
 IgA IF, all LPs % IgA (CSF) 0 (0-34.2; 110) 0 (0-31.7; 82) 0 (0-34.2; 20) 0 (0-31.7; 38) 0 (0-13.3; 37) 0 (0-0; 6)
 IgA IF, QIgA positives % IgA (CSF) 13.3 (3.8-34.2; 5) 9.5 (3.8-31.7; 4) 34.2 (34.2-34.2; 1) 17.8 (3.8-31.7; 2) 9.5 (5.7-13.3; 2) n.a. (n.a.; 0)
 IgA IF, > 10% Samples 3/110 (2.7%) 2/82 (2.4%) 1/20 (5%) 1/38 (2.6%) 1/37 (2.7%) 0/6 (0%)
 IgA Loc, all LPs mg/l 0 (0-2.9; 106) 0 (0-2.9; 79) 0 (0-2; 19) 0 (0-2.9;36) 0 (0-0.5; 36) 0 (0-0; 6)
 IgA Loc, QIgA positives mg/l 0.5 (0.2-2.9; 5) 0.5 (0.2-2.9; 4) 2 (2-2; 1) 1.6 (0.4-2.9; 2) 0.4 (0.2-0.5; 2) n.a. (n.a.; 0)
 IgA CSF mg/l 3.6 (0-40.7; 109) 3.57 (0-40.7; 81) 4.4 (0-29.1; 19) 4.34 (0-40.7; 36) 3.1 (0-7.99; 38) 3.4 (0-10.4; 6)
 IgA serum g/l 1.95 (0.25-7; 108) 1.8 (0.62-7; 81) 2.3 (1.1-3; 19) 1.77 (0.62-7; 37) 2.04 (0.73-5.16; 37) 1.94 (0.67-3.99; 6)
  1. Quotients, concentrations, and fractions are given as median and range
  2. QIgG/A/M CSF/serum IgG/A/M ratio; IgG/A/M IF intrathecally produced IgG/IgA/IgM fraction; IgG/A/M loc locally (intrathecally) produced IgG/A/M; LP lumbar puncture